19th International Workshop on Co‑morbidities and Adverse Drug Reactions in HIV

88 Pages·2017·0.93 MB·English

Abstracts presented at the
19th International Workshop on Co‑morbidities
and Adverse Drug Reactions in HIV
Milan, Italy, 23–25 October 2017
cover page.indd 1 25/10/2017 10:08:58
ORGANIZING COMMITTEE
Chairs for 2017
Todd T Brown Johns Hopkins University, Baltimore, MD, USA
Andrew Carr St Vincent’s Hospital, Sydney, Australia
Giovanni Guaraldi University of Modena, Modena, Italy
Jacqueline Capeau Faculty of Medicine Saint Antoine, INSERM, Paris, France
David Cooper University of New South Wales, Sydney, Australia
Stefan Mauss Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
Kathleen Mulligan University of California at San Francisco, CA, USA
Peter Reiss Academic Medical Center, Amsterdam, the Netherlands
Morrie Schambelan University of California at San Francisco, CA, USA
SCIENTIFIC COMMITTEE
Judith Currier University of California, Los Angeles, CA, USA
Michael Dubé University of Southern California, Los Angeles, CA, USA
Julian Falutz Immune Deficiency Treatment Center, Montreal General Hospital, Montreal, Canada
Steve Grinspoon Massachusetts General Hospital, Boston, MA, USA
Carl Grunfeld University of California Medical Center, San Francisco, CA, USA
Giovanni Guaraldi University of Modena, Modena, Italy
Donald Kotler Columbia University, New York, NY, USA
Jules Levin The National AIDS Treatment Advocacy Project, New York, NY, USA
Jens Lundgren University of Copenhagen, Hvidovre, Denmark
Esteban Martínez IDIPAPS - Hospital Clinic, University of Barcelona, Barcelona, Spain
Graeme Moyle Chelsea and Westminster Hospital, London, UK
Pablo Tebas University of Pennsylvania, Philadelphia, PA, USA
Sharon Walmsley University Health Network, Toronto, Canada
Kevin Yarasheski Washington University, St Louis, MO, USA
PLENARY SPEAKERS
Stefan D Anker University Medical Center Göttingen, Göttingen, Germany
Juliet Compston University of Cambridge, Cambridge, UK
David Cooper University of New South Wales, Sydney, Australia
Stefano Del Prato University of Pisa, Pisa, Italy
Sven Enerback University of Gothenburg, Gothenburg, Sweden
ORGANIZING SECRETARIAT
International Medical Press Admiral House
76–78 Old Street
London, EC1V 9AZ, UK
Tel: [phone]
Fax: [phone]
www.intmedpress.com/comorbidities
[email protected]
19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV
Prelims_2017_web.indd 5 25/10/2017 10:17:36
ABSTRACT CONTENTS
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
ORAL PRESENTATIONS
Session 1
A3 Frailty predicts recurrent but not single falls 10 years later in HIV+ and O01
HIV- women
A Sharma
A5 Influence of HIV infection on the development of sarcopenia in O02
HIV-infected subjects
P Echeverría
A6 Longitudinal analysis of quality of life (QOL) in HIV-positive and O03
HIV-negative subjects enrolled to the UPBEAT (Understanding the
Pathology of Bone Disease in HIV Infected Subjects) cohort study after
5 years of follow-up
E Alvarez
Session 2
A7 Patterns of co-occurring comorbidities in people living with HIV O04
D De Francesco
A8 Changes in lipid parameters, body fat, bone mineral density and O05
inflammation/immune activation markers in middle-aged HIV-infected
patients with viral suppression treated with etravirine/raltegravir –
results at week 48 of the ANRS163-ETRAL trial
J Capeau
A9 African mitochondrial DNA haplogroup L2 is associated with increased O06
b-cell function and protection from incident diabetes mellitus in
HIV-seropositive African American women
TT Brown
Session 3
A10 Effect of vitamin D supplementation on bone turnover markers (BTMs) O07
during HIV pre-exposure prophylaxis (PrEP) using tenofovir disoproxil
fumarate-emtricitabine (TDF-FTC) in men who have sex with men (MSM).
A matched case-control substudy of CCTG 595
MP Dubé
A11 Baseline bone mineral density in a cohort of young HIV-infected women O08
using tenofovir and Depo-Provera
F Matovu Kiweewa
A12 Relationships between bone density, bone quality and reported fractures O09
within the HIV UPBEAT cohort
T McGinty
A13 Rate of progression to osteoporosis in a large cohort of HIV-infected O10
subjects
A Bonjoch
19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xv
Prelims_2017_web.indd 15 25/10/2017 10:17:38
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
Session 4
A14 A randomized, double-blinded, placebo-controlled trial of the dipeptidyl O11
peptidase-4 (DPP-4) inhibitor sitagliptin for reducing inflammation and
immune activation in treated and suppressed HIV infection: ACTG 5346
MP Dubé
A15 Analysis of serum metabolomics parameters associated with carotid O12
intima-media thickness (c-IMT) and inflammation in HIV-infected,
never-smoker men, naive of ART or ART-controlled, compared with
matched HIV-negative controls
J Capeau
A16 Prospective analysis of lipid compositional changes with antiretroviral O13
therapy (ART) and immune activation in persons living with HIV
NT Funderburg
A17 HIV disease progression is controlled by cell cholesterol homeostasis O14
dysregulation in antigen presenting cells
G Rappocciolo
Session 5
A18 HIV increases renal complications, hospitalization and mortality in O15
diabetes mellitus
G Lui
A19 Utility of chronic kidney disease (CKD) risk prediction scores and the O16
changing prevalence of CKD in HIV-positive individuals
JM Trevillyan
A20 Investigating the effect of antiretroviral switch to tenofovir alafenamide O17
on lipid profiles in people living with HIV within the UCD ID Cohort
A Lacey
Session 6
A21 Tenofovir exposure is associated with low bone mineral density but not O18
increased trabecular bone score
R Bedimo
A22 Bone density, microarchitecture and tissue quality after 48-weeks and O19
96-weeks of treatment with tenofovir disoproxil fumarate
R Güerri-Fernández
A23 Impact of antiretroviral treatment containing tenofovir difumarate on O20
telomere length attrition in a prospective cohort of aviraemic
HIV-infected participants
R Montejano
A25 A randomized comparison of integrase inhibitors with TDF/FTC on renal O21
markers
G Moyle
Session 7
A26 Associations between subcutaneous fat density and metabolic and O22
inflammatory biomarkers differ by HIV serostatus and are independent of
fat quantity
JE Lake
xvi Programme & Abstracts
Prelims_2017_web.indd 16 25/10/2017 10:17:38
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
A27 Intrahepatic triglyceride is more strongly associated with insulin-resistant O23
glucose metabolism than visceral adiposity in HIV, and is improved with
tauroursodeoxycholic acid treatment
DN Reeds
A28 Alterations of adipose tissue induced by HIV or SIV infection: Tat and O24
Nef-induced senescence and fibrosis
J Gorwood
POSTER PRESENTATIONS
Adipocyte biology, insulin resistance & lipid metabolism
A31 Compromised macrophage-mediated HIV trans infection of CD4+ T cells P01
in non-progressors is linked to DC-SIGN expression and lipid raft
dissociation
DC DeLucia
A32 Evaluation of lipid levels in HIV-infected patients after being switched P02
from a tenofovir disoproxil fumarate to a tenofovir alafenamide
containing-regimen in a clinic in Puerto Rico
I Melendez-Rivera
A33 Underdiagnosis and suboptimal care of diabetes mellitus in a French P03
HIV-infected cohort in 2016
L Slama
A34 MicroRNA expression profiling in a couple of monozygotic twins P04
discordant for HIV infection: focus on the potential lipodystrophy
biomarkers
N Squillace
Aging & associated disorders
A35 Impact of a mobile health application (‘App’) on clinical outcome and P05
satisfaction of older HIV-infected patients as an emerging tool for care,
education and prevention
P Echeverría
A36 Aging in HIV-infected and uninfected populations: a comprehensive P06
geriatric assessment
P Echeverría
A37 Compression of frailty at an older age an aging population infected with P07
HIV: a ‘geriatric-HIV’ modelling study
G Guaraldi
A38 Internet illiteracy as a barrier to use of a web-based health promotion P08
resource among elderly HIV patients
G Guaraldi
A39 Feasibility and long-term assessment of physical and behavioural P09
functioning among older adults with HIV
G Guaraldi
A40 HIV and aging in Lebanon: an exploratory study of unmet health needs P10
among a cohort of PLHIV
NM Melhem
19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xvii
Prelims_2017_web.indd 17 25/10/2017 10:17:38
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
Body composition
A41 Prevalence and predictors of sarcopenia in a large HIV-infected cohort P11
characterized with nutrition and physical activity data
G Guaraldi
A42 Trunk fat increases consistently in HIV-infected adults on antiretroviral P12
therapy, with patterns differing by sex
JE Lake
A43 Visceral adiposity is increased in the setting of HIV infection but is not P13
associated with increased inflammation
BS Taylor
Bone metabolism & toxicities
A45 The relationship between physical activity and bone mineral density: P14
results from the SATURN HIV Study
JD Perazzo
A46 Polypharmacy and osteopenia/osteoporosis in HIV infection: are drugs P15
other than antiretrovirals implicated?
N Squillace
Cardiovascular disease
A47 ApoB/ApoA ratio is associated with subclinical atherosclerosis in treated P16
HIV patients
M Arnedo
A48 Decreased oxidative stress and endothelial dysfunction: potential P17
mechanisms for cardioprotective effect of atazanavir
R Bedimo
A49 Determinants of uncontrolled blood pressure in treated hypertensive P18
adults living with HIV
F Boccara
A50 Nycthemeral blood pressure variation in hypertensive adults living P19
with HIV. Description of non-dipping hypertension
F Boccara
A51 Usefulness of 24-h ambulatory blood pressure monitoring in adults living P20
with HIV
F Boccara
A52 Switching from boosted protease inhibitors (PI/r) to dolutegravir (DTG) in P21
virologically suppressed HIV-infected patients with high cardiovascular
risk: 48-week effects on subclinical cardiovascular disease
E Martinez
A53 Contribution of aggressive cardiovascular risk factor screening to detect P22
vascular peripheric disease and coronaropathy in HIV-treated patients
L Slama
A54 Use of lipid-lowering therapy (LLT) and achievement of recommended P23
targets in an aging cohort of people living with HIV
A Lacey
xviii Programme & Abstracts
Prelims_2017_web.indd 18 25/10/2017 10:17:38
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
Clinical management of ADRs
A55 Discontinuation of dolutegravir- and elvitegravir-containing cART in the P24
Netherlands; incidence rates and risk factors
PDJ Bollen
A56 Aging with HIV: a new challenge to manage polypharmacy and P25
antiretroviral therapy – a nationwide survey of cART-related adverse
drug reactions
C Allavena
A57 Safety analysis of German real-life cohort WIP shows low rates of P26
neuropsychiatric events leading to discontinuation of raltegravir therapy
B Funke
A58 Assessing potentially inappropriate prescribing in community-dwelling P27
older HIV patients using the STOPP-START criteria
G Guaraldi
A59 Pharmacist review of medications for HIV-positive people seen in general P28
practice (PROM-GP)
KF Mackie
A60 Occurrence of hypersensitivity reaction and hepatotoxicity in patients P29
receiving integrase inhibitors: results from the EuroSIDA study
L Shepherd
A61 Failure of antiretroviral therapy (ART) in Australian adults is mainly due P30
to ART toxicity
KJ Siefried
A62 Polypharmacy of concomitant medications in HIV-infected Australian P31
adults is common, and associated with adverse effects
KJ Siefried
A63 Socioeconomic and psychosocial factors are associated with suboptimal P32
outcomes in HIV-infected adults: a case-control analysis
KJ Siefried
Liver disease & hepatotoxicity
A65 Clinical, immunological and virological evolution in HIV/HCV-coinfected P33
patients 12 and 24 weeks after direct-acting antiviral agents treatment
TF Aiello
A66 HIV infection does not affect hepatic steatosis or fibrosis P34
DP Kotler
A67 Incidence of didanosine-related liver disease in HIV-positive individuals P35
in British Columbia
SA Lother
A68 Does antiretroviral therapy affect ALT levels in HIV/HCV-coinfected patients P36
after SVR (GECCO)?
S Mauss
A69 An audit of coinfected patients with HIV, treated for hepatitis C in 1 year P37
at a single UK centre
L Taylor
19th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xix
Prelims_2017_web.indd 19 25/10/2017 10:17:38
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
Other co-morbidities (cancer, neurocognitive disorders and renal toxicities)
A71 Gender differences in ART treatment outcomes in Taiwan – a matched P38
case control study in a tertiary care hospital
C-C Shih
A72 Case study: cutaneous vasculitis in the setting of dolutegravir initiation P39
VJ Cornelisse
A73 Validity of the ViovFit2 activity tracker in measuring steps in community P40
dwelling HIV-infected geriatric patients
G Guaraldi
A74 Respiratory symptoms, lung structural and functional abnormalities in a P41
cohort of never-smoking HIV-infected patients: comparison with
HIV-negative controls
G Guaraldi
A75 Neurocognitive impairment is associated in virally suppressed P42
HIV-infected persons who are aging
G Guaraldi
A76 Pancreatic insufficiency in patients with long-lasting HIV infection P43
S Grützmeier
A77 Chronic kidney disease in Australian HIV-infected patients: analysis of P44
the Australian HIV Observational Database
CC O’Connor
A78 Real-life experience of switching from integrase strand transfer P45
inhibitors (INSTIs) to darunavir/cobicistat (DRV/c), because of toxicity
or intolerance
A Rodríguez-Da Silva
A79 Abacavir usage patterns and hypersensitivity reactions (HSR) in the P46
EuroSIDA cohort
A Roen
A80 Prevalence and risk factors of HIV neurocognitive disorders (HAND) in a P47
Spanish HIV cohort
M Sanmartí
xx Programme & Abstracts
Prelims_2017_web.indd 20 25/10/2017 10:17:38
ORAL PRESENTATIONS
Orals.indd 1 04/10/2017 09:19:07
Orals.indd 2 04/10/2017 09:19:07